查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1169093

預防性疫苗市場：按疫苗類型、疾病類型（肺炎球菌,脊髓灰質炎病毒,肝炎,流感,麻疹,腮腺炎,風疹,其他）,地區-規模,份額,前景,機會分析2022-2028

Preventive Vaccines Market, By Vaccine Type, By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella, and Other Disease Types), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預防性疫苗可保護人們免受嚴重和危及生命的感染。 這些疫苗可幫助免疫系統更快、更有效地對抗感染。 疫苗是預防兒童和成人嚴重疾病的最有效方法之一。 因此，隨著傳染病流行的加劇，全球對預防性疫苗的需求也在迅速增加。

市場動態

預計在預測期內將發生幾次傳染病流行、疫苗接種需求增加、COVID-19 爆發、加強疫苗研發的舉措不斷增加以及對疫苗開發的關注度增加。這是預計推動增長的主要因素全球預防性疫苗市場的增長。

例如，美國和德國在 COVID-19 疫苗研發方面的投資最大，分別投入約 20 億美元和 15 億美元。 輝瑞和 BioNTech 在美國開發了第一個獲得許可的 COVID-19 疫苗，已獲得約 8 億美元的研發資金。 此外，2022 年 1 月，Daiichi Sankyo Co., Ltd. 宣布已在日本開始試驗，以研究針對新型冠狀病毒感染（COVID-19）的 mRNA 疫苗 DS-5670 的加強給藥。

這項研究的主要特點

  • 本報告對全球預防性疫苗市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2028 年）的市場規模和復合年增長率 (CAGR%)。
  • 它還揭示了不同細分市場的潛在創收機會，並為市場勾勒出一個有吸引力的投資建議矩陣。
  • 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 它根據以下參數介紹了全球預防性疫苗市場的主要參與者，包括公司亮點、產品組合、主要亮點、財務業績和戰略。
  • 本研究涵蓋的主要公司包括賽諾菲公司、輝瑞公司、Novavax 公司、默克公司、強生公司、葛蘭素史克公司、第一三共株式會社、Emergent BioSolutions Inc.、阿斯利康和武田製藥有限公司等。
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 《全球預防疫苗市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球預防性疫苗市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 市場概況：按疫苗類型分類
    • 按疾病類型劃分的市場概況
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 世界上傳染病的增加
    • 疫苗開發成本高
    • COVID-19 爆發（全球大流行）
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章全球預防性疫苗市場：冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學
  • 供應方和需求方分析
  • 經濟影響

第 5 章全球預防性疫苗市場：按疫苗類型分類，2017-2028

  • 活疫苗/減毒疫苗
  • 滅活□□疫苗
  • 亞單位疫苗
  • 類毒素疫苗
  • 其他疫苗類型

第 6 章全球預防性疫苗市場：按疾病類型分類，2017-2028

  • 肺炎球菌
  • 脊髓灰質炎病毒
  • 肝炎
  • 流感
  • 麻疹、腮腺炎和風疹 (MMR)
  • 其他疾病類型

第 7 章。全球預防性疫苗市場：按地區劃分，2017-2028

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 世界其他地方

第八章競爭格局

  • Sanofi SA
  • Pfizer Inc.
  • Novavax Inc.
  • Merck & Co. Inc.
  • Johnson & Johnson
  • GlaxoSmithKline PLC,
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited

第九章

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5342

Preventive vaccines protect people from serious and life-threatening infectious diseases. These vaccines help immune system fight infections faster and more effectively. Vaccines are one of the most effective ways to prevent serious disease in children and adults. Therefore, with the increase in prevalence of infectious diseases, the demand for preventive vaccines is also increasing with the rapid pace around the world.

Market Dynamics:

Increase in prevalence of several infectious diseases, increase in demand for vaccination, outbreak of COVID-19, rising initiatives to enhance R&D of vaccines, and increase in focus on the vaccine development are major factors expected to drive growth of the global preventive vaccines market during the forecast period.

For instance, the United States and Germany have been the largest investors in COVID-19 vaccine R&D, pouring around US$ 2 billion and US$ 1.5 billion into the effort, respectively. Pfizer and BioNTech, who developed the first COVID-19 vaccine authorized in the U.S., received around US$ 800 million in R&D funding. Moreover, in January 2022, Daiichi Sankyo Company, Limited announced that it has initiated a trial in Japan to investigate a booster dose of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19).

Key features of the study:

  • This report provides in-depth analysis of the global preventive vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global preventive vaccines market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Sanofi SA, Pfizer Inc., Novavax Inc., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline PLC, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., AstraZeneca, and Takeda Pharmaceutical Company Limited, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global preventive vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preventive vaccines market.

Detailed Segmentation:

  • Global Preventive Vaccines Market By Vaccine Type:
    • Live/Attenuated Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • Toxoid Vaccines
    • Other Vaccine Types
  • Global Preventive Vaccines Market By Disease Type:
    • Pneumococcal
    • Poliovirus
    • Hepatitis
    • Influenza
    • Measles, Mumps, and Rubella (MMR)
    • Other Disease Types
  • Global Preventive Vaccines Market By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Sanofi SA
    • Pfizer Inc.
    • Novavax Inc.
    • Merck & Co. Inc.
    • Johnson & Johnson
    • GlaxoSmithKline PLC
    • Daiichi Sankyo Co. Ltd.
    • Emergent BioSolutions Inc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Vaccine Type
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of infectious diseases around the world
    • High cost of vaccine development
    • The outbreak of COVID-19 (global pandemic)
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Preventive Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Preventive Vaccines Market, By Vaccine Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Live/Attenuated Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Inactivated Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Subunit Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Toxoid Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Vaccine Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Preventive Vaccines Market, By Disease Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Pneumococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Poliovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Hepatitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Measles, Mumps, and Rubella (MMR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Disease Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Preventive Vaccines Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

  • Sanofi SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novavax Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co. Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC,
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Daiichi Sankyo Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emergent BioSolutions Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us